Perjeta (Pertuzumab) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The perjeta (pertuzumab) market size has grown rapidly in recent years. It will grow from $1.08 million in 2025 to $1.26 million in 2026 at a compound annual growth rate (CAGR) of 15.7%. The growth in the historic period can be attributed to approval of her2 monoclonal antibodies, increasing breast cancer incidence, advancements in her2 diagnostics, strong clinical trial results, oncology guideline inclusion.

The perjeta (pertuzumab) market size is expected to see rapid growth in the next few years. It will grow to $2.23 million in 2030 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to growth of her2 positive patient identification, expansion into adjuvant therapy settings, increased combination regimen adoption, rising oncology drug spending, global market penetration. Major trends in the forecast period include expansion of her2 targeted combination therapies, growing use in early and metastatic breast cancer, rising adoption of dual her2 blockade, increased focus on precision oncology, improved survival outcomes in her2 positive patients.

The rising incidence of breast cancer is expected to drive the growth of the Perjeta (pertuzumab) market in the coming years. Breast cancer is a disease in which malignant cells develop in breast tissue, often originating in the ducts or lobules. The increasing prevalence of breast cancer is attributed to lifestyle factors such as higher rates of obesity and sedentary behavior, as well as improved early detection through widespread screening programs. Perjeta (pertuzumab) is used to treat HER2-positive breast cancer by targeting the HER2 receptor and is typically combined with trastuzumab and chemotherapy to enhance treatment outcomes. For example, in October 2023, Ray of Light Wales, a UK-based not-for-profit charity, reported that approximately 600,000 people in the UK were living after a breast cancer diagnosis, with projections indicating this number could double to 1.2 million by 2030. Therefore, the rising incidence of breast cancer is driving the Perjeta (pertuzumab) market.

A key trend in the Perjeta (pertuzumab) market is the development of technologically advanced solutions, such as subcutaneous combination therapies, to improve patient outcomes and treatment convenience. Subcutaneous combination therapies involve combining two or more drugs in a single injection administered under the skin. For instance, in November 2023, Chugai Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, launched Phesgo, a subcutaneous combination treatment for HER2-positive breast cancer and advanced or recurrent HER2-positive colorectal cancer. This innovative therapy combines the monoclonal antibodies pertuzumab and trastuzumab with vorhyaluronidase alfa, allowing administration in just 5 to 8 minutes, significantly reducing the time required compared to traditional intravenous infusions. Phesgo is indicated for patients with advanced or recurrent HER2-positive colorectal cancer and represents the first subcutaneous option for this condition.

In June 2024, Zydus Pharmaceuticals, an India-based pharmaceutical company, partnered with Dr. Reddy’s Laboratories to enhance access to a pertuzumab biosimilar for HER2-positive breast cancer patients in India. This collaboration aims to improve affordability, availability, and patient outcomes through combined distribution efforts. Dr. Reddy’s Laboratories, also based in India, manufactures pertuzumab biosimilars.

Major companies operating in the perjeta (pertuzumab) market are Roche Holding AG.

North America was the largest region in the perjeta (pertuzumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the perjeta (pertuzumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the perjeta (pertuzumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the perjeta market by increasing costs for monoclonal antibody production inputs, biologics manufacturing equipment, and cold-chain logistics. These pressures are most evident in hospital oncology treatment settings. North america and europe face pricing challenges due to biologics import reliance. However, tariffs are promoting localized biologic production and regional manufacturing partnerships. This enhances supply chain resilience and long-term treatment availability.

The perjeta (pertuzumab) market research report is one of a series of new reports that provides perjeta (pertuzumab) market statistics, including perjeta (pertuzumab) industry global market size, regional shares, competitors with a perjeta (pertuzumab) market share, detailed perjeta (pertuzumab) market segments, market trends and opportunities, and any further data you may need to thrive in the perjeta (pertuzumab) industry. This perjeta (pertuzumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Perjeta (pertuzumab) is a targeted therapy used to treat certain types of breast cancer. It is a monoclonal antibody that binds specifically to the human epidermal growth factor receptor 2 (HER2), a protein that promotes the growth of cancer cells in HER2-positive breast cancer.

The main forms of Perjeta (pertuzumab) are human source and animal source. Although Perjeta is a monoclonal antibody developed using recombinant DNA technology and produced in mammalian cell lines, animal-derived components may be used during the production process. Its products include monoclonal antibodies and other biologic drugs, indicated for conditions such as early breast cancer and metastatic breast cancer. Perjeta is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The perjeta (pertuzumab) market consists of sales of products including herceptin, docetaxel, paclitaxel, and carboplatin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.